Social Media Ideas for Biologics

<![CDATA[Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change]]>

Bone Biologics Bets on a More Selective Path to Spine Fusion

For most of the past two decades, the orthobiologics shelf has been defined by a familiar tradeoff.

Sports Medicine Biologics Market Research Report 2026-2031: Demand for Faster Recovery and Reduced Downtime Drives Marke...

August 19, 2026 05:21 ET  | Source: Research and Markets Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) — The “Sports Medicine Biologics…

<![CDATA[Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform]]>

Vivex Biologics Launches VIA Linxâ„¢, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advan...

New molecular medical device joins Vivex's growing suite of allograft and advanced wound care technologies.

Celonic and Leukocare Collaborate to Support Complex Biologics and Advanced Drug Development

The collaboration brings together Celonic’s expertise in cell line development, drug substance process development, intensified bioprocessing, and GMP manufacturing with Leukocare’...

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders

Attovia Therapeutics’ biologic medicines could offer advantages over currently available immune disorder drugs, such as Sanofi’s blockbuster medicine Dupixent. The IPO comes as Att...

UK’s MHRA Accepts Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment

LOR, the first approval-stage drug candidate with disease-modifying potential for osteoarthritis, is now under assessment in the United…

Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product

With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that offers pipeline-in-a-product potential addressing a target that has clinical and regulatory...

FDA approves two autoinjector formulations for Stelara biosimilar

The FDA has approved a pair of prefilled autoinjector formulations for the Stelara biosimilar ustekinumab-kfce, according to a press release from the manufacturer.Ustekinumab-kfce...

Orthobiologics registry needs vertifiable data

Few areas of orthopedic practice have grown faster and with thinner evidence than orthobiologics. Platelet-rich plasma has moved from the periphery of sports medicine to our office...

Orthobiologics registry needs vertifiable data

Few areas of orthopedic practice have grown faster and with thinner evidence than orthobiologics. Platelet-rich plasma has moved from the periphery of sports medicine to our office...

The Private Label Biosimilar Paradox in Medicare Part D

By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...

BioLab Holdings Adds FastSkin® Autologous Wound Care Technology to Tissue Restoration Portfolio

BioLab Holdings has partnered with mimiX AWC to add FastSkin® Patch, a whole blood clot technology that creates personalized bioactive tissue from a patient's own blood in about 10...

<![CDATA[Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera...

BioLab Holdings Adds FastSkin®Autologous Wound Care Technology to Tissue Restoration Portfolio

NEWS PROVIDED BY BioLab Holdings, Inc.  Aug 19, 2026, 13:02 ET PHOENIX, Aug. 19, 2026 /PRNewswire/ — As part of…

FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints

NEWS PROVIDED BY FibroBiologics, Inc.  Aug 18, 2026, 08:30 ET Animal trials show cartilage repair within four weeks…